Evaluation of Epithelial Cell Adhesion Molecule, Galectin-3, and Proliferative Cell Nuclear Antigen Expression in Thyroid Papillary Carcinomas and Their Lymph Node Metastases

ArticleAçık Erişim

Özet

Background: Thyroid papillary carcinoma (PTC) is the most common carcinoma of thyroid carcinomas and endocrine carcinomas. The diagnosis of thyroid PTC is made mainly by the presence of nuclear features such as nuclear clearing, groove, and nuclear inclusions. Some benign lesions of the thyroid may have nuclear features and growth patterns of papillary thyroid carcinomas, which can make the differential diagnosis difficult. Different immunohistochemical markers have always been needed to reduce diagnostic errors and detect malignancies in routine practice. As in all tumor cases, studies continue to understand carcinogenesis in thyroid carcinomas. One of the ways that can help understand this involves the use of new and effective immunohistochemical markers. Aim: This study aimed to examine the expression of epithelial cell adhesion molecule (EpCAM), Galectin-3 (Gal-3), and proliferative cell nuclear antigen (PCNA), which are immunohistochemical markers that may contribute to the diagnosis and prognosis of thyroid PTCs and lymph node (LN) metastases. Materials and Methods: EpCAM, Gal-3, and PCNA immunohistochemical markers were applied to 26 unifocal (UF) thyroid PTC cases and 25 thyroid PTC cases with LN metastasis or multifocal (MF) tumor field. Results: It was observed that the Gal-3 staining score decreased significantly in the LN metastasis focus compared to the UF tumor. With EpCAM significant loss of membranous expression was observed in the MF tumor compared to the UF tumor. There was no statistically significant difference between the case groups in terms of PCNA staining score. Conclusions: These results may be important in terms of obtaining new immunohistochemical clues for diagnosis and carcinogenesis in thyroid PTCs and their metastases. The number of cases in our study is limited, and we think that supporting the results with a large series of studies may contribute to the diagnosis and prognosis of the patients. © 2026 Nigerian Journal of Clinical Practice.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10201Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.4103/njcp.njcp_346_24Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorDaltaban, F.
dc.contributor.authorSayar, I.
dc.contributor.authorTayfur, M.
dc.contributor.authorGürbüzel, M.
dc.contributor.authorBalcı, M.
dc.date.accessioned2026-10-18T20:25:27.715872955Z
dc.date.available2026-10-18T20:25:27.715872955Z
dc.date.issued2026
dc.description.abstractBackground: Thyroid papillary carcinoma (PTC) is the most common carcinoma of thyroid carcinomas and endocrine carcinomas. The diagnosis of thyroid PTC is made mainly by the presence of nuclear features such as nuclear clearing, groove, and nuclear inclusions. Some benign lesions of the thyroid may have nuclear features and growth patterns of papillary thyroid carcinomas, which can make the differential diagnosis difficult. Different immunohistochemical markers have always been needed to reduce diagnostic errors and detect malignancies in routine practice. As in all tumor cases, studies continue to understand carcinogenesis in thyroid carcinomas. One of the ways that can help understand this involves the use of new and effective immunohistochemical markers. Aim: This study aimed to examine the expression of epithelial cell adhesion molecule (EpCAM), Galectin-3 (Gal-3), and proliferative cell nuclear antigen (PCNA), which are immunohistochemical markers that may contribute to the diagnosis and prognosis of thyroid PTCs and lymph node (LN) metastases. Materials and Methods: EpCAM, Gal-3, and PCNA immunohistochemical markers were applied to 26 unifocal (UF) thyroid PTC cases and 25 thyroid PTC cases with LN metastasis or multifocal (MF) tumor field. Results: It was observed that the Gal-3 staining score decreased significantly in the LN metastasis focus compared to the UF tumor. With EpCAM significant loss of membranous expression was observed in the MF tumor compared to the UF tumor. There was no statistically significant difference between the case groups in terms of PCNA staining score. Conclusions: These results may be important in terms of obtaining new immunohistochemical clues for diagnosis and carcinogenesis in thyroid PTCs and their metastases. The number of cases in our study is limited, and we think that supporting the results with a large series of studies may contribute to the diagnosis and prognosis of the patients. © 2026 Nigerian Journal of Clinical Practice.
dc.identifier.doi10.4103/njcp.njcp_346_24
dc.identifier.eissn2229-7731
dc.identifier.endpage355
dc.identifier.issn1119-3077
dc.identifier.issue3
dc.identifier.pmid41912470
dc.identifier.scopus2-s2.0-105034704460
dc.identifier.startpage350
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10201
dc.identifier.volume29
dc.identifier.wosWOS:001728656700006
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofNigerian Journal of Clinical Practice
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectImmunohistochemical markers
dc.subjectlymph node
dc.subjectmetastasis
dc.subjectthyroid papillary carcinoma
dc.subjectAdult
dc.subjectBiomarkers, Tumor
dc.subjectCarcinoma, Papillary
dc.subjectEpithelial Cell Adhesion Molecule
dc.subjectFemale
dc.subjectGalectin 3
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectLymphatic Metastasis
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectProliferating Cell Nuclear Antigen
dc.subjectThyroid Cancer, Papillary
dc.subjectThyroid Neoplasms
dc.subjectcycline
dc.subjecttumor marker
dc.subjecthuman
dc.subjectlymph node metastasis
dc.subjectmetabolism
dc.subjectpapillary carcinoma
dc.subjectpathology
dc.subjectthyroid tumor
dc.titleEvaluation of Epithelial Cell Adhesion Molecule, Galectin-3, and Proliferative Cell Nuclear Antigen Expression in Thyroid Papillary Carcinomas and Their Lymph Node Metastases
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentDepartment of Pathology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Türkiye. | Department of Medical Biology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Türkiye.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)